Ivax to market Qvar
Executive Summary
Ivax will market CFC-free asthma inhaler Qvar (beclomethasone dipropionate) in U.S. under licensing agreement with 3M. Ivax also gets non-exclusive worldwide license to certain 3M patents covering HFA formulations of various asthma drugs. 3M will manufacture Qvar under long-term contract. The product has been on the market since Oct. 2000...
You may also be interested in...
Ivax Qvar pediatric approval
Ivax' CFC-free asthma inhaler Qvar (beclomethasone) receives supplemental approval May 10 for use in children ages 5-11. FDA is reviewing whether Qvar will receive additional exclusivity with the pediatric approval. Ivax markets Qvar under an agreement with 3M (1"The Pink Sheet" April 8, In Brief)...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.